Abstract: The present invention relates to the field of medicine. It relates more particularly to a product suppressing or reducing the expression or activity of the human small nucleolar RNA (snoRNA) of sequence SEQ ID NO: 1 for use as a medicament. The product of the invention is preferably for use for preventing or treating cancer. The description further relates to vectors, cells, vehicles and compositions capable of delivering and expressing a product suppressing or reducing the expression or activity of the human small nucleolar RNA (snoRNA) of sequence SEQ ID NO: 1, and to uses thereof.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: A conveyor comprises an endless belt and a belt return device. The endless belt comprises an upper run and a lower run and is configured to convey conveying material in a conveying direction. An intermediate space is defined between the upper run and the lower run. The belt return device facilitates transitioning of the endless belt between the lower run and the upper run. The endless belt defines at least one passage opening which allows the exit of at least a portion of an intermediate space material which is formed by a portion of the conveying material which has reached the intermediate space. At least a portion of the endless belt comprises a conveyor track and a passage track. The passage track defines the at least one passage opening. The conveyor track and the passage track are arranged side by side in the conveying direction.

Abstract: An apparatus for electrically connecting at least four electrical conductors includes a connecting element and at least four shielding pipes, which are each provided for receiving at least one conductor. In order to enable a simple and economical connection, the connecting element forms pipe connection pieces and each connection piece is integrally joined or materially bonded to a respective shielding pipe.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.

Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.

Abstract: An apparatus for electrically connecting at least four electrical conductors includes a connecting element and at least four shielding pipes, which are each provided for receiving at least one conductor. In order to enable a simple and economical connection, the connecting element forms pipe connection pieces and each connection piece is integrally joined or materially bonded to a respective shielding pipe.

Abstract: The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.

Abstract: The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

Abstract: The present invention concerns the use of particular RNA sequences as a medicament. More precisely, it concerns the use of small nucleolar RNAs (snoRNAs) which the inventor has shown to be involved in the mechanisms of aging. The snoRNAs of the invention can be used in particular to increase the stress resistance of a subject and to fight against the harmful effects of aging, typically for preventing or treating a degenerative disease, a laminopathy, diabetes, obesity or a cancer and, more generally, to prolong the lifespan of a subject. The snoRNAs of the invention can also be used in the treatment of infertility. The invention further relates to vectors, cells, transgenic animals and compositions capable of expressing an snoRNA of the invention, and methods using any of the above products of the invention as a tool for identification of a molecule active in the prevention or treatment of a pathology, abnormality or disorder linked to a mechanism of aging.

Abstract: A connection element for electrically conductive connections of at least four electric conductors. The connection element has a metallic electrode which has a cavity for merging the conductors and an opening into the cavity for each conductor. At least the outer surface of the electrode is surrounded with a paper insulation.

Abstract: Provided herein are methods, compositions, and kits for treating IgA nephropathy and Henoch-Schönlein purpura nephritis using BAFF inhibitors, including blisibimod.

Abstract: An irradiation facility for a nuclear reactor, a method of removing thermal heat from an irradiated object and adjusting an energy distribution/neutron/gamma-ray flux ratio of irradiation, and a product obtainable by the method.

Abstract: The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

Abstract: The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

Abstract: The present invention concerns the use of particular RNA sequences as a medicament. More precisely, it concerns the use of small nucleolar RNAs (snoRNAs) which the inventors have shown to be involved in the mechanisms of aging. The snoRNAs of the invention can be used in particular to increase the stress resistance of a subject, to fight against the harmful effects of aging, typically for preventing or treating a degenerative disease, a laminopathy, diabetes, obesity or a cancer and, more generally, to prolong the lifespan of a subject. The snoRNAs of the invention can also be used in the treatment of infertility. The invention further relates to vectors, cells, transgenic animals and compositions capable of expressing a snoRNA of the invention, and methods using any of the above products of the invention as a tool for identification of a molecule active in the prevention or treatment of a pathology, abnormality or disorder linked to a mechanism of aging.

Abstract: A connection element for electrically conductive connections of at least four electric conductors. The connection element has a metallic electrode which has a cavity for merging the conductors and an opening into the cavity for each conductor. At least the outer surface of the electrode is surrounded with a paper insulation.

Abstract: The present invention relates to compounds of formulas III and V that are useful as pharmaceutical agents, particularly as autophagy inhibitors.